The Protein Journal

, Volume 31, Issue 8, pp 651–655 | Cite as

Desferal as Improving Agent for Hemoglobin Fructation: Structural and Functional Impacts

  • Naghmeh Sattarahmady
  • Hossein Heli
  • Ali A. Moosavi-Movahedi


Hyperglycemia and advanced glycation end products (AGEs) have considerable effects in diabetic patients. So, the recognition of anti-glycation property of compounds has a substantial benefit. Here, desferal, an iron chelator which is one of the most effective drugs in β-thalassemia patients, was chosen to explore its effects on the fructation process of hemoglobin (Hb). The results indicated that desferal had a retardation effect on the functional and structural changes of Hb during fructation. It can prevent the AGE and carbonyl formations and helix depletion during the Hb fructation process. Moreover, desferal can preserve peroxidase and esterase activities of fructated Hb similar as native Hb. Therefore, desferal can be introduced as an anti-glycation drug to prevent the AGE formation.


Hemoglobin Fructose Glycation Desferal 



Advanced glycation end products


Circular dichroism


Differential scanning calorimetry




Sample of hemoglobin incubated with 50 mM fructose


Sample of hemoglobin incubated with 50 mM fructose +  250 μM desferal




Sample of fresh hemoglobin + 250 μM desferal


p-Nitrophenyl acetate


Reactive oxygen species


Trichloroacetic acid





We would like to thank Research Councils of Shiraz University of Medical Sciences (Project No.: 3799) and Razi festival foundation.


  1. 1.
    Bakhti M, Habibi-Rezaei M, Moosavi-Movahhedi AA, Khazaei MR (2007) J Biochem 141:827–833CrossRefGoogle Scholar
  2. 2.
    Bhattacherjee A, Chakraborti AS (2011) Inter J Biol Macromol 48:202–209CrossRefGoogle Scholar
  3. 3.
    Bose T, Chakraborti AS (2008) Biochim Biophys Acta 1780:800–880CrossRefGoogle Scholar
  4. 4.
    Brittenham GM, Griffith PM, Nienhuis AW, Mclaren CE, Young NS, Tucker EE, Allen CJ, Farrell DE, Harris JW (1994) N Engl J Med 331:567–573CrossRefGoogle Scholar
  5. 5.
    Brownlee M (2000) Metabolism 49:9–13CrossRefGoogle Scholar
  6. 6.
    Budzikiewicz H (2010) In: Kinghorn AD, Falk H, Kobayashi J (eds) Progress in the chemistry of organic natural products. Springer, New YorkGoogle Scholar
  7. 7.
    Bunn HF, Higgins PJ (1981) Science 213:222–224CrossRefGoogle Scholar
  8. 8.
    Chowdhury TA, Lasker SS (1998) Postgrad Med J 74:480–481CrossRefGoogle Scholar
  9. 9.
    Elbaum D, Nagel RL (1981) J Biol Chem 256:2280–2283Google Scholar
  10. 10.
    Everse J, Johnson MC, Marini MA (1994) Methods Enzymol 231:547–561CrossRefGoogle Scholar
  11. 11.
    Gabutti V, Piga A (1996) Acta Haemotol 95:26–36CrossRefGoogle Scholar
  12. 12.
    GhoshMoulick R, Bhattacharya J, Roy S, Basak S, Dasgupta AK (2007) Biochim Biophys Acta 1774:233–242CrossRefGoogle Scholar
  13. 13.
    Heli H, Mirtorabi S, Karimian K (2011) Expert Opin Ther Pat 21(6):818–856CrossRefGoogle Scholar
  14. 14.
    Lapolla A, Traldi P, Fedele D (2005) Clin Biochem 38:103–115CrossRefGoogle Scholar
  15. 15.
    Levine RL, Garland D, Oliver CN, Amici A, Climent I, Lenz A, Ahn B, Shaltiel S, Stadtman ER (1991) Methods Enzymol 208:464–478Google Scholar
  16. 16.
    Nagai R, Murray DB, Metz TO, Baynes JW (2012) Diabetes 61:549–559CrossRefGoogle Scholar
  17. 17.
    Sattarahmady N, Khodagholi F, Moosavi-Movahedi AA, Heli H, Hakimelahi GH (2007) Int J Biol Macromol 41(2):180–184CrossRefGoogle Scholar
  18. 18.
    Sattarahmady N, Moosavi-Movahedi AA, Ahmad F, Hakimelahi GH, Habibi-Rezaei M, Saboury AA, Sheibani N (2007) Biochim Biophys Acta 1770:933–942CrossRefGoogle Scholar
  19. 19.
    Sattarahmady N, Moosavi-Movahedi AA, Habibi-Rezaei M (2011) J Med Biochem 30(1):5–10CrossRefGoogle Scholar
  20. 20.
    Sattarahmady N, Moosavi-Movahedi AA, Habibi-Rezaei M, Ahmadian S, Saboury AA, Heli H, Sheibani N (2008) Carbohydr Res 343:2229–2234CrossRefGoogle Scholar
  21. 21.
    Schalkwijk GC, Stehouwer CDA, Hinsberg VWM (2004) Diabetes Metab Res Rev 20:369–382CrossRefGoogle Scholar
  22. 22.
    Sen S, Bose T, Roy A, Chakraborti AS (2007) Mol Cell Biochem 301:251–257CrossRefGoogle Scholar
  23. 23.
    Sharifi E, Sattarahmady N, Habibi-Rezaei M, Farhadi M, Sheibani N, Moosavi-Movahedi AA (2009) Protein Pept Lett 16(6):653–659CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Naghmeh Sattarahmady
    • 1
    • 2
    • 3
  • Hossein Heli
    • 4
  • Ali A. Moosavi-Movahedi
    • 5
  1. 1.Department of Medical Physics, School of MedicineShiraz University of Medical SciencesShirazIran
  2. 2.Department of Nanomedicine, School of Advanced Medical Sciences and TechnologiesShiraz University of Medical SciencesShirazIran
  3. 3.Pharmaceutical Sciences Research Center, School of PharmacyShiraz University of Medical SciencesShirazIran
  4. 4.Department of Chemistry, Science and Research BranchIslamic Azad UniversityFarsIran
  5. 5.Institute of Biochemistry and BiophysicsUniversity of TehranTehranIran

Personalised recommendations